ICON Public (NASDAQ:ICLR) Given New $350.00 Price Target at Barclays

ICON Public (NASDAQ:ICLR) had its target price lowered by Barclays from $355.00 to $350.00 in a research report sent to investors on Friday morning, Benzinga reports. The brokerage currently has an overweight rating on the medical research company’s stock.

A number of other research firms have also issued reports on ICLR. William Blair reiterated an outperform rating on shares of ICON Public in a research note on Friday, May 31st. Truist Financial upped their target price on shares of ICON Public from $367.00 to $383.00 and gave the company a buy rating in a research note on Friday. Evercore ISI dropped their price target on shares of ICON Public from $350.00 to $330.00 and set an outperform rating on the stock in a research note on Friday, April 26th. TD Cowen upped their price objective on shares of ICON Public from $349.00 to $373.00 and gave the company a buy rating in a research report on Friday, May 31st. Finally, Mizuho reaffirmed a buy rating and set a $346.00 target price on shares of ICON Public in a research report on Thursday, April 4th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of $352.56.

ICON Public Trading Up 3.3 %

Shares of ICLR stock opened at $323.46 on Friday. The company has a quick ratio of 1.21, a current ratio of 1.31 and a debt-to-equity ratio of 0.36. ICON Public has a fifty-two week low of $221.20 and a fifty-two week high of $347.72. The firm’s 50 day moving average price is $322.17 and its two-hundred day moving average price is $308.60. The stock has a market cap of $26.69 billion, a price-to-earnings ratio of 39.35, a price-to-earnings-growth ratio of 1.40 and a beta of 1.23.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, July 24th. The medical research company reported $3.75 earnings per share for the quarter, beating the consensus estimate of $3.68 by $0.07. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The business had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same quarter in the previous year, the business posted $2.96 EPS. The business’s quarterly revenue was up 4.1% on a year-over-year basis. On average, analysts anticipate that ICON Public will post 14.54 EPS for the current year.

Institutional Trading of ICON Public

Several hedge funds and other institutional investors have recently bought and sold shares of ICLR. CIBC Private Wealth Group LLC grew its position in shares of ICON Public by 0.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 695,932 shares of the medical research company’s stock worth $196,998,000 after acquiring an additional 6,331 shares in the last quarter. Motco boosted its holdings in ICON Public by 196.1% in the fourth quarter. Motco now owns 3,823 shares of the medical research company’s stock worth $1,082,000 after purchasing an additional 2,532 shares during the period. State of Tennessee Treasury Department increased its stake in ICON Public by 4.9% during the fourth quarter. State of Tennessee Treasury Department now owns 155,797 shares of the medical research company’s stock valued at $44,101,000 after purchasing an additional 7,270 shares during the last quarter. Cullen Investment Group LTD. bought a new stake in ICON Public during the fourth quarter valued at $1,620,000. Finally, Prime Capital Investment Advisors LLC acquired a new stake in shares of ICON Public during the fourth quarter worth $416,000. 95.61% of the stock is owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.